WO1991016305A1 - Composes d'ethenediyle heterocyclique qui inhibent la kinase de tyrosine de recepteur egf - Google Patents

Composes d'ethenediyle heterocyclique qui inhibent la kinase de tyrosine de recepteur egf Download PDF

Info

Publication number
WO1991016305A1
WO1991016305A1 PCT/US1991/002597 US9102597W WO9116305A1 WO 1991016305 A1 WO1991016305 A1 WO 1991016305A1 US 9102597 W US9102597 W US 9102597W WO 9116305 A1 WO9116305 A1 WO 9116305A1
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
patient
cell proliferation
patient suffering
pharmaceutically acceptable
Prior art date
Application number
PCT/US1991/002597
Other languages
English (en)
Inventor
Alfred P. Spada
Paul E. Persons
Alexander Levitzki
Chaim Gilon
Aviv Gazit
Original Assignee
Rhone-Poulenc Rorer International (Holdings), Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rhone-Poulenc Rorer International (Holdings), Inc. filed Critical Rhone-Poulenc Rorer International (Holdings), Inc.
Priority to AU77568/91A priority Critical patent/AU662480B2/en
Priority to JP91508377A priority patent/JPH05507072A/ja
Publication of WO1991016305A1 publication Critical patent/WO1991016305A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57—Nitriles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring

Definitions

  • This invention relates to the inhibition of cell proliferation. More specifically, this invention relates to the use of heterocyclicethenediyl compounds in inhibiting cell proliferation, including compounds which are useful protein tyrosine kinase (PTK) inhibitors.
  • PTK protein tyrosine kinase
  • Normal cellular reproduction is believed to be triggered by the exposure of the cellular substrate to one or more growth factors, examples of which are insulin, epidermal growth factor (EGF) and platelet-derived growth factor (PDGF) .
  • growth factors are typically specific for corresponding growth factor receptors which are imbedded in and which penetrate through the cellular membrane.
  • EGF epidermal growth factor
  • PDGF platelet-derived growth factor
  • Such growth factors are typically specific for corresponding growth factor receptors which are imbedded in and which penetrate through the cellular membrane.
  • This growth factor-receptor binding alters the chemical characteristics of that portion of the receptor which exists within the cell and which functions as an enzyme to catalyze phosphorylation of either an intracellular substrate or the receptor itself, the latter being referred to as autophosphorylation.
  • phosphorylation enzymes include tyrosine kinases, which catalyze phosphorylation of tyrosine amino acid residues of substrate proteins.
  • diseased states are characterized by the uncontrolled reproduction of cells. These diseased states involve a variety of cell types and include disorders such as leukemia, cancer, psoriasis, atherosclerosis and restenosis injuries.
  • the inhibition of tyrosine kinase is believed to have utility in the control of uncontrolled cellular reproduction, i.e., cellular proliferative disorders.
  • Initiation of autophosphorylation i.e., phosphorylation of the growth factor receptor itself, and of the phosphorylation of a host of intracellular substrates are some of the biochemical events which are involved in mitogenesis and cell proliferation.
  • Autophosphorylation of the insulin receptor and phosphorylation of substrate proteins by other receptors are the earliest identifiable biochemical hormonal responses.
  • PTK protein tyrosine kinase
  • EGF epidermal growth factor
  • EGF receptors inhibit EGF-induced proliferation of A431/clone 15 cells with little or no effect on the proliferation of such cells when induced by other growth factors. It has been reported also that erbstatin inhibits the autophosphorylation of the EGF receptor in membranes of A431 cells. Low concentrations of erbstatin are reguired to inhibit EGF receptor autophosphorylation, whereas much higher concentra ⁇ tions of erbstatin are required to inhibit cyclic adenosine 3' ,5'-monophosphate (cAMP)-dependent protein kinase.
  • cAMP cyclic adenosine 3' ,5'-monophosphate
  • a method of inhibiting cell proliferation in a patient suffering from such disorder comprising the administration to the patient of a heteroarylethenediyl or a heteroarylethenediyl aryl compound, or a pharmaceutically acceptable salt thereof, exhibiting protein tyrosine kinase inhibition activity, wherein the heteroaryl group can be ono- or bicyclic heteroaryl and the aryl group can be mono- or bicyclic heteroaryl or bi- or tricyclic carbocyclic, said compound optionally substituted or polysubstituted, provided that the heteroaryl group is not furyl or thienyl when the ethenediyl group has geminal cyano substituents.
  • compositions comprising, in admixture with a pharmaceutically acceptable carrier, a pharmaceutically- effective amount of the aforementioned type of compound.
  • Still another aspect of the present invention relates to novel compounds of the aforementioned type.
  • W is a heteroaryl ring system having an about 5- to about 7- membered monocyclic ring including 1 or 2 N, 0 or S atoms, or an about 8- to about 12-membered bicyclic ring including 1 to about 4 N, O or S atoms, said ring system optionally substituted with one to about three R 4 groups;
  • R- is alkyl, -CN, -CONRR, -CSNRR or -C00R;
  • R is hydrogen, alkyl or aralkyl
  • Rj is a ino, -CONH 2 ,
  • each R ⁇ - is independently hydrogen, alkyl, hydroxy, alkoxy or halo
  • each R 7 is independently alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
  • n 0 to about 6;
  • n 1 to about 7;
  • Alkyl means a saturated aliphatic hydrocarbon which may be either straight- or branch-chained containing from about 1 to about 6 carbon atoms.
  • “Lower alkyl” means an alkyl group as above, having 1 to about 4 carbon atoms which may be straight- or branch-chained such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl or tert-butyl.
  • Alkoxy means an alkyl-oxy group in which "alkyl” is as previously described. Lower alkoxy groups are preferred. Exemplary groups include methoxy, ethoxy, n-propoxy, i-propoxy and n-butoxy.
  • Aryl means an unsaturated or partially unsaturated ring system. Preferred aryl groups are pyridyl and indolyl.
  • acyl means an organic radical derived from an organic acid, a carboxylic acid, by the removal of its acid hydroxyl group.
  • Preferred acyl groups are lower alkyl carboxylic acid groups such as acetyl and propionyl. Benzoyl is also preferred.
  • Halo means a halogen.
  • Preferred halogens include chloride, bromide and fluoride.
  • Preferred aralkyl groups are benzyl and phenethyl.
  • PTK inhibiting compounds should be competitive with the substrate of EGF receptor tyrosine kinase (EGFRK) and not with adenosine triphosphate (ATP) .
  • EGFRK EGF receptor tyrosine kinase
  • ATP adenosine triphosphate
  • the PTK inhibitors quercetin and genistein, which compete with ATP, inhibit other protein kinases and as a result are highly cytotoxic.
  • compounds which inhibit EGFRK better than they inhibit insulin receptor kinase (IRK) and/or PDGF receptor kinase are of considerable value.
  • solubility of the compounds of the present invention both in water and in mildly hydrophobic solvents will enhance the probability that they traverse the cell membrane.
  • Various insoluble compounds have exhibited significant EGFRK inhibition in jLn vitro testing.
  • a preferred class of compounds useful in the practice of the present invention include those described by Formula I where:
  • W is a 5- or 6-membered monocyclic aryl ring including 1 or 2 N, 0 or S atoms, or a 9- or 10-membered bicyclic aryl ring including 1 to 4 N, 0 or S atoms, said ring optionally substituted with one to about three R 4 groups;
  • R- is -CN, -CONRR, -CSNRR or -COOR;
  • R is hydrogen, alkyl, or aralkyl
  • R 2 is -W, -CN, -CONHR-, -CONRR, -COOR, -CSNRR or
  • R 3 is hydrogen; ⁇ each R, is independently alkyl, hydroxy, alkoxy or halo;
  • R 5 is amino, -CONH 2 ,
  • each Rg is independently hydrogen or alkyl
  • each R 7 is independently alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
  • n 0-4;
  • n 2-6;
  • W is furyl, pyrrolyl, thienyl, thiazolyl, pyridyl, imidazolyl, isoimidazolyl, pyridazinyl, pyrimdinyl, benzofuran l, indolyl, indolinyl, indolinonyl, benzothienyl, benzothiazolyl, quinolinyl, isoquinolinyl, chromenyl, 1,3-benzodioxolyl or 2,3-dihydro-l,4-benzodioxinyl.
  • W is pyridyl, indolyl, imidazolyl, benzothiazolyl, 1,3- benzodioxolyl or 2,3-dihydro-l,4-benzodioxinyl;
  • R- is -CN, -CONRR, -CSNRR or -COOR;
  • R is hydrogen, alkyl, or aralkyl
  • R 2 is -W, -CN, -CONHR-, -CONRR, -COOR, -CSNRR or
  • R 3 is hydrogen
  • each R 4 is independently lower alkyl, hydroxy, lower alkoxy or halo
  • each R 7 is independently lower alkyl, hydroxy, alkoxy, halo, nitro, carboxy or carbalkoxy;
  • n 0-4;
  • n 2-6.
  • Acid addition salts may be formed and are simply a more convenient form for use; in practice, use of the salt form inherently amounts to use of the base form.
  • the acids which can be used to prepare the acid addition salts include preferably those which produce, when combined with the free base, pharmaceutically acceptable salts, that is, salts whose anions are non-toxic to . the animal organism in pharmaceutical doses of the salts, so that the beneficial properties inherent in the free base are not vitiated by side effects ascribable to the anions.
  • Pharmaceutically acceptable salts within the scope of the invention include those derived from the following acids: mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid and sulfamic acid; and organic acids such as acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, quinic acid, and the like.
  • mineral acids such as hydrochloric acid, sulfuric acid, phosphoric acid and sulfamic acid
  • organic acids such as acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, quinic
  • the corresponding acid addition salts comprise the following: hydrochloride, sulfate, phosphate, sulfamate, acetate, citrate, lactate, tartarate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate, respectively.
  • the acid addition salts of the compounds of this invention are prepared either by dissolving the free base in aqueous or aqueous-alcohol solution or other suitable solvents containing the appropriate acid and isolating the salt by evaporating the solution, or by reacting the free base and acid in an organic solvent, in which case the salt separates directly or can be obtained by concentration of the solution.
  • Knoevenagel condensation of a heterocyclic aldehyde of formula W in a polar media with an active methylene compound of the formula R,CH 2 R 2 in the presence of ammonia or amines such as piperidine and raised heat results in the products of this invention.
  • the corresponding ketone starting material is used. Reaction temperatures in the range of 25°C to reflux and reaction times vary depending on the materials being used in the condensation.
  • R, R,, R 2 , R 3 , R 4 , R 5 , Rg and R 7 substituents on the hetero ring or chain can be present in the starting compound or added after formation of the condensation product by methods known in the art for substitution or conversion on one group to another. If the substituents themselves are reactive, then the substituents can themselves be protected according to the techniques known in the art. A variety of protecting groups known in the art, may be employed. Examples of many of these possible groups may be found in "Protective Groups in Organic Synthesis" by T. W. Green, John Wiley and Sons, 1981.
  • nitro groups can be added to the aromatic ring by nitration and the nitro group converted to other groups, such as amino by reduction, and halo by diazotization of the amino group and replacement of the diazo group.
  • Acyl groups can be substituted onto the aryl groups by Friedel-Crafts acylation. The acyl groups can then be transformed to the corresponding alkyl groups by various methods, including the Wolff-Kishner reduction and Clemmenson reduction.
  • Amino groups can be alkylated to form mono- and di-alkylamino groups; and mercapto and hydroxy groups can be alkylated to form corresponding ethers.
  • Primary alcohols can be oxidized by oxidizing agents known in the art to form carboxylic acids or aldehydes, and secondary alcohols can be oxidized to form ketones.
  • substitution or alteration reactions can be employed to provide a variety of substituents throughout the molecule of the starting material, intermediates, or the final product.
  • Compounds within the scope of this invention exhibit significant activity as protein tyrosine kinase inhibitors and possess therapeutic value as cellular antiproliferative agents for the treatment of certain conditions including, for example, psoriasis and restenosis injuries. It is expected that the invention will be particularly applicable to the treatment of atherosclerosis. With regard to the treatment of some conditions, for example, atherosclerosis, certain people may be identified as being at high risk, for example, due to genetic, environmental or historical factors. Compounds within the scope of the present invention can be used in preventing or delaying the occurrence or reoccurrence of such conditions or otherwise treating the condition.
  • Compounds of the present invention can be administered to a mammalian host in a variety of forms adapted to the chosen route of administration, i.e., orally, or parenterally.
  • Parenteral administration in this respect includes administration by the following routes: intravenous, intramuscular, subcutaneous, intraocular, intrasynovial, transepithelial including transdermal, ophthalmic, sublingual and buccal; topically including ophthalmic, dermal, ocular, rectal and nasal inhalation via insufflation and aerosol and rectal systemic.
  • the active compound may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or it may be enclosed in hard or soft shell gelatin capsules, or it may be compressed into tablets, or it may be incorporated directly with the food of the diet.
  • the active compound may be incorporated with excipient and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like.
  • Such compositions and preparations should contain at least 0.1% of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2 to about 6% of the weight of the unit.
  • the amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained.
  • Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between about 1 and 1000 mg of active compound.
  • the tablets, troches, pills, capsules and the like may also contain the following: A binder such as gum tragacanth, acacia, corn starch or gelatin; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen, or cherry flavoring.
  • a binder such as gum tragacanth, acacia, corn starch or gelatin
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose or saccharin may be added or a flavoring agent such as peppermint,
  • tablets, pills, or capsules may be coated with shellac, sugar or both.
  • a syrup or elixir may contain the active compound, sucrose as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts employed.
  • the active compound may be incorporated into sustained-release preparations and formulations.
  • the active compound may also be administered parenterally or intraperitoneally.
  • Solutions of the active compound as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
  • Dispersion can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions.
  • the form must be sterile and must be fluid to the extent that easy syringability exists. It may be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (for example, glycerol, propylene glycol, and liquid polyethylene glycol, and the like) , suitable mixtures thereof, and vegetable oils.
  • the proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants.
  • the prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by use of agents delaying absorption, for example, aluminum monostearate and gelatin.
  • Sterile injectable solutions are prepared by incorporating the active compound in the required amount in the appropriate solvent with various of the other ingredients enumerated above, as required, followed by filtered sterilization.
  • dispersions are prepared by incorporating the various sterilized active ingredient into a sterile vehicle which contains the basic dispersion medium and the required other ingredients from those enumerated above.
  • the preferred methods of preparation are vacuum drying and the freeze drying technique which yield a powder of the active ingredient plus any additional desired ingredient from previously sterile-filtered solution thereof.
  • the therapeutic compounds of this invention may be administered to a mammal alone or in combination with pharmaceutically acceptable carriers, as noted above, the proportion of which is determined by the solubility and chemical nature of the compound, chosen route of administration and standard pharmaceutical practice.
  • the dosage of the present therapeutic agents which will be most suitable for prophylaxis or treatment will vary with the form of administration, the particular compound chosen and the physiological characteristics of the particular patient under treatment. Generally, small dosages will be used initially and if necessary, will be increased by small increments until the optimum effect under the circumstances is reached.
  • the therapeutic human dosage based on physiological studies using rats, will generally be from about 0.01 mg to about 100 mg/kg of body weight per day or from about 0.4 mg to about 10 g or and higher although it may be administered in several different dosage units from once to several times a day. Oral administration requires higher dosages.
  • Examples l- 11 below are illustrative of compounds within the scope of the present invention.
  • Examples 1-5 illustrate various unsubstituted heteroaryl malononitriles, i.e., R, and R 2 are each -CN and the other R substituents are all hydrogen.
  • Example 7 illustrates a nitro-substituted heteroaryl malononitrile, i.e., R t and R 2 are each -CN, R 3 is hydrogen and R 4 is nitro.
  • Example 8 illustrates a diheteroarylethenediyl compound, i.e., R t is -CN, R 2 is pyridyl and the other R substituents are all hydrogen.
  • Example 9 illustrates a heteroarylethenediyl carbocyclic compound, i.e., R- is hydrogen, R 2 is phenanthryl, R 3 is -CN and there are no !_, substituents.
  • Examples 10 and 11 illustrate heteroarylethenediyl aryl compounds, i.e., R- is -CN,. R 2 is 3,4-dihydroxybenzoyl and R 3 is -H.
  • EGF-receptor purification is based on the procedure of Yarden and Schlessinger. A431 cells are grown in 80 cm 2 bottles to confluency (2 x 10 7 cells per bottle) . The cells are washed twice with PBS and harvested with PBS containing
  • EDTA 1.0 mmol EDTA (1 hour at 37°C) , and centrifuged at 600g for 10 . minutes.
  • the cells are solubilized in 1 ml per 2 x 10 7 cells of cold solubilization buffer (50 mmol Hepes buffer, pH 7.6, 1% Triton X-100, 150 mmol NaCl, 5 mmol EGTA, 1 mmol PMSF, 50 ⁇ g/ml aprotinin, 25 mmol benzamidine, 5 ⁇ g/ml leupeptic, and 10 ⁇ g/ml soybean trypsin inhibitor) for 20 minutes at 4°C.
  • cold solubilization buffer 50 mmol Hepes buffer, pH 7.6, 1% Triton X-100, 150 mmol NaCl, 5 mmol EGTA, 1 mmol PMSF, 50 ⁇ g/ml aprotinin, 25 mmol benzamidine, 5 ⁇ g/ml leupeptic, and 10
  • the supernatant is loaded onto a WGA-agarose column (100 ⁇ l of packed resin per 2 x 10 7 cells) and shaken for 2 hours at 4°C.
  • the unabsorbed material is removed and the resin washed twice with HTN buffer (50 mmol Hepes, pH 7.6, 0.1% Triton X-100, 150 mmol NaCl) , twice with HTN buffer containing 1 M NaCl, and twice with HTNG buffer (50 mmol Hepes, pH 7.6, 0.1% Triton X- 100, 150 mmol NaCl, and 10% glycerol).
  • the EGF receptor is eluted batchwise with HTNG buffer containing 0.5 M N-acetyl-D- glucosamine (200 ⁇ l per 2 x 10 7 cells) .
  • the eluted material is stored in aliquots at -70°C and diluted before use with TMTNG buffer (50 mmol Tris-Mes buffer, pH 7.6, 0.1% Triton X-100, 150 mmol NaCl, 10% glycerol) .
  • WGA-purified EGFR (0.25 ⁇ g/assay) is preactivated with
  • EGF (0.85 ⁇ M) in 50 mmol Tris-Mes buffer, pH 7.6 for 20 minutes at 4°C.
  • the assay is initiated by addition of a mixture which contains Mg(Ac) 2 (60 mmol), [7- 32 P]ATP (125 ⁇ M, 2- 5 ⁇ Ci/assay) , poly(GAT) (0.0625 mg/ml, 0.125 mg/ml, 0.25 mg/ml) , and six concentrations of inhibitor in duplicates.
  • the temperature of the assay is 22°C and the production of phosphorylated copolymer is found to be linear up to 20 minutes.
  • the PTK inhibitors tested are solubilized in water or a mixture of ethanol and water such that the final concentration of ethanol does not exceed 4% in the assay. Up to 4% ethanol in the assay has no effect on the EGFR kinase activity.
  • the concentration of EGF in the assay is 300 nM in a final volume of 40 ⁇ l. After 5, 10 or 20 minutes, aliquots of 25 ⁇ l are applied onto Whatman 3-mm paper cuttings, which are then soaked in cold 10% TCA containing 0.01 M sodium pyrophosphate. After being washed overnight at 4°C, the paper cuttings are dried and counted, measuring 32 P Cerenkov radiation.
  • results of this assay indicate that the compounds of the present invention are effective in inhibiting substrate phosphorylation catalyzed by EGFRK.
  • WGA-purified EGF receptor from A431 cells (0.5 ⁇ g/assay) is activated with EGF (800 nM) for 20 minutes at 4°C.
  • the reaction is initiated by the addition of Mg(Ac) 2 (60 mmol) , Tris-Mes buffer, pH 7.6 (50 mmol), and [ 32 P]ATP (20 ⁇ M, 5 ⁇ Ci/assay) .
  • the reaction is conducted at either 4 or 15°C and terminated by addition of sodium dodecyl sulfate (SDS) sample buffer (10% glycerol, 50 mmol Tris, pH 6.8, 5% ⁇ -mercapto- ethanol, and 3% (SDS) .
  • SDS sodium dodecyl sulfate
  • the samples are run on a 8% SDS polyacrylamide gel (SDS-PAGE) (prepared from 30% acrylamide and 0.8% bis-(acrylamide) and contained 0.375 M Tris, pH 8.8, 0.1% SDS, 0.05% TEMED, and 0.46% ammonium persulfate) .
  • SDS-PAGE SDS polyacrylamide gel
  • the gel is dried and autoradiography performed with Agfa Curix RP2 X-ray film.
  • the relevant radioactive bands are cut and counted in the Cerenkov mode.
  • the fast phase of autophosphorylation continues for another 10 minutes.
  • the extent of phosphorylation completed in the first 10-s at 15°C comprises 1/3 of the total autophosphorylation signal and probably reflects the phosphorylation of the first site on the receptor.
  • the 10-s interval is therefore chosen for use in subsequent autophosphorylation experiments.
  • WGA-purified EGF receptor from A431 cells 0.5 ⁇ g/assay is activated with EGF (0.85 ⁇ M) for 20 minutes at 4°C.
  • the assay is performed at 15°C and initiated by addition of Mg(Ac) 2 (60 mmol), Tris-Mes buffer, pH 7.6 (50 mmol), [ 3 P]ATP (carrier free, 5 ⁇ Ci/assay) , and increasing concentrations of nonradioactive ATP.
  • the assay is terminated after 10-s by addition of SDS sample buffer.
  • the samples are run on a 6% SDS polyacrylamide gel. The gel is dried and autoradiographed as described above.
  • the relevant radioactive bands are cut and counted in the Cerenkov mode, the K m for ATP determined in this fashion is found to be 7.2 ⁇ M. With use of the 10-s assay protocol, the EGF concentration dependence of EGFRK autophosphorylation is determined.
  • Rat liver membranes are prepared from the livers of 6- week-old rats as described by Cuatrecasas.
  • WGA-purified insulin receptor is prepared according to Zick et al.
  • WGA- purified rat liver InsRK (1.25 ⁇ g) is preincubated with or without 330 nM insulin in 50 mmol Tris-Mes buffer, pH 7.6, for 30 minutes at 22°C.
  • the assay is performed at 22°C and initiated by addition of a mixture which contains Mg(Ac) 2 (60 mmol), NaV0 3 (40 ⁇ M) , [7- 3 P]ATP (125 ⁇ M, 3-5 ⁇ Ci/assay) , and poly(GT) [poly(Glu 4 Tyr) ] at three concentrations: whenever an inhibitor is tested, it is added at the proper concentration.
  • the final concentration of insulin in the assay is 125 nM.
  • the total volume of the assay is 40 ⁇ l. After 20 minutes, aliquots of 30 ⁇ l are applied on Whatman 3-mm paper and soaked in cold 10% TCA, containing 0.01 M sodium pyrophosphate. After being washed overnight, the papers are dried and counted, measuring Cerenkov radiation.
  • the InsRk-catalyzed phosphorylation of poly(GT) obeys Michaelis-Menten kinetics.
  • A431 cells were grown to confluence on human fibronectin coated tissue culture dishes. After washing 2 times with ice- cold PBS, cells were lysed by the addition of 500 ⁇ l/dish of lysis buffer (50 mmol Hepes, pH 7.5, 150 mmol NaCl, 1.5 mmol Mg Cl 2 , 1 mmol EGTA, 10% glycerol, 1% triton X-100, 1 mmol PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin) and incubating 5 minutes at 4°C.
  • lysis buffer 50 mmol Hepes, pH 7.5, 150 mmol NaCl, 1.5 mmol Mg Cl 2 , 1 mmol EGTA, 10% glycerol, 1% triton X-100, 1 mmol PMSF, 1 mg/ml aprotinin, 1 mg/ml leupeptin
  • Example EGF PDGF 8 1 20 The results of this assay show that the compounds of the present invention inhibit EGF receptor kinase better than they inhibit PDGF receptor kinase.
  • Costar dishes pre-coated with human fibronectin by incubating for 30 minutes at room temperature with 10 ⁇ g/0.5 ml/well) .
  • the cells were grown to confluence for 2 days.
  • the medium was changed to DMEM containing 0.5 calf serum for 36-48 hours and the cells were then incubated with EGF (Toyobo, New York, NY) (20 ng/ l) or serum (10% calf serum) and different concentrations of the inhibitory compounds.
  • EGF Toyobo, New York, NY
  • serum 10% calf serum
  • HER 14 and K721A were prepared by transfecting N1H3T3 cells (clone 2.2) (From C. Fryling, NCI, NIH) , which lack endogenous EGF-receptors, with cDNA constructs of wild-type EGF-receptor or mutant EGF-receptor lacking tyrosine kinase activity (in which Lys 721 at the ATP- binding site was replaced by an Ala residue, respectively) . All cells were grown in DMEM with 10% calf serum (Hyclone, Logan, Utah) .

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Des composés hétéroaryléthènediyle ou hétéroaryléthènediyle aryle dans lesquels le groupe hétéroaryle peut être un hétéroaryle monocyclique ou bicyclique et le groupe aryle peut être hétéroaryle monocyclique ou bicyclique ou carbocyclique bicyclique ou tricyclique, ledit composé étant éventuellement substitué ou polysubstitué, à condition que le groupe hétéroaryle ne soit pas furyle ou thiényle lorsque le groupe éthènediyle possède des substituants cyano géminés, et des compositions pharmaceutiques comprenant ces composés, et leur utilisation pour inhiber la prolifération de cellules chez un patient souffrant de cette maladie.
PCT/US1991/002597 1990-04-16 1991-04-16 Composes d'ethenediyle heterocyclique qui inhibent la kinase de tyrosine de recepteur egf WO1991016305A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU77568/91A AU662480B2 (en) 1990-04-16 1991-04-16 Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase
JP91508377A JPH05507072A (ja) 1990-04-16 1991-04-16 Ｅｇｆレセプタチロシンキナーゼを阻害する複素環式エテンジイル化合物

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50998190A 1990-04-16 1990-04-16
US509,981 1990-04-16

Publications (1)

Publication Number Publication Date
WO1991016305A1 true WO1991016305A1 (fr) 1991-10-31

Family

ID=24028875

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1991/002597 WO1991016305A1 (fr) 1990-04-16 1991-04-16 Composes d'ethenediyle heterocyclique qui inhibent la kinase de tyrosine de recepteur egf

Country Status (6)

Country Link
EP (1) EP0527181A4 (fr)
JP (1) JPH05507072A (fr)
AU (1) AU662480B2 (fr)
CA (1) CA2080582A1 (fr)
IL (1) IL97873A0 (fr)
WO (1) WO1991016305A1 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584222A1 (fr) * 1991-05-10 1994-03-02 Rhone Poulenc Rorer Int Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf.
WO1995026341A1 (fr) * 1994-03-28 1995-10-05 Pharmacia S.P.A. Derives beta-aryle et beta-heteroaryle-alpha-cyanoacrylamides substitues en tant qu'inhibiteurs de la tyrosine kinase
WO1996039387A1 (fr) * 1995-06-06 1996-12-12 American Home Products Corporation Acrylonitriles diheterocycliques inhibiteurs de la proliferation des cellules des muscles lisses
WO1996039391A1 (fr) * 1995-06-06 1996-12-12 American Home Products Corporation Derives de styryl benzimidazole inhibiteurs de la proliferation des cellules musculaires lisses
EP0770601A1 (fr) * 1995-05-10 1997-05-02 Kyowa Hakko Kogyo Co., Ltd. Derives de propenone
EP0833629A2 (fr) * 1995-06-19 1998-04-08 Ontogen Corporation Derives d'acide aryl-acrylique convenant comme inhibiteurs de proteine-tyrosine-phosphatase
US7745468B2 (en) 2003-12-11 2010-06-29 Board of Regents, University of Texas Systems The Compounds for treatment of cell proliferative diseases
US8637675B2 (en) 2008-07-08 2014-01-28 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS)
US8779151B2 (en) 2006-03-31 2014-07-15 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
EP3429569A4 (fr) * 2016-03-17 2020-02-26 The Johns Hopkins University Méthodes destinées à prévenir ou à traiter la maladie de parkinson par farnésylation de paris

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2159618T3 (es) * 1993-11-17 2001-10-16 Kyowa Hakko Kogyo Kk Derivados de propenona.
ATE259353T1 (de) * 1995-12-01 2004-02-15 Kyowa Hakko Kogyo Kk Propenonderivate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069230A (en) * 1975-06-04 1978-01-17 Sumitomo Chemical Company, Limited Preparation of indole derivatives

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU632992B2 (en) * 1987-12-24 1993-01-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising benzylidene- and cinnamylidene-malononitrile derivatives for the inhibition of proliferative processes in mammalian cells, certain such novel compounds and their preparation
GB9004483D0 (en) * 1990-02-28 1990-04-25 Erba Carlo Spa New aryl-and heteroarylethenylene derivatives and process for their preparation
EP0525109A4 (en) * 1990-04-16 1993-06-30 Rhone-Poulenc Rorer International (Holdings) Inc. Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit egf receptor tyrosine kinase

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4069230A (en) * 1975-06-04 1978-01-17 Sumitomo Chemical Company, Limited Preparation of indole derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEMICAL ABSTRACTS, Volume 70, No. 23, issued June 9, 1969 (Columbus, Ohio, US) KATO et al., "Synthesis of methylpyridine derivatives. XXB. Synthesis of alphasubstited 2-pyridine acewnitrieles", Abstract No. 106, 329-Z Yakagaku zasshi 89 (2) 188-193 (1969). *
See also references of EP0527181A4 *

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0584222A4 (en) * 1991-05-10 1994-07-06 Rhone Poulenc Rorer Int Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
EP0584222A1 (fr) * 1991-05-10 1994-03-02 Rhone Poulenc Rorer Int Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf.
US5652250A (en) * 1994-03-28 1997-07-29 Pharmacia S.P.A. N-substituted β-aryl- and β-heteroaryl-α-cyanoacrylamide derivatives and process for their preparation
WO1995026341A1 (fr) * 1994-03-28 1995-10-05 Pharmacia S.P.A. Derives beta-aryle et beta-heteroaryle-alpha-cyanoacrylamides substitues en tant qu'inhibiteurs de la tyrosine kinase
AU685599B2 (en) * 1994-03-28 1998-01-22 Pharmacia S.P.A. Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors
EP0770601A4 (fr) * 1995-05-10 1998-08-05 Kyowa Hakko Kogyo Kk Derives de propenone
EP0770601A1 (fr) * 1995-05-10 1997-05-02 Kyowa Hakko Kogyo Co., Ltd. Derives de propenone
US6444694B1 (en) 1995-06-06 2002-09-03 Wyeth Styryl benzimidazole derivatives
US5710164A (en) * 1995-06-06 1998-01-20 American Home Products Corporation Diheterocyclic styryl nitriles
WO1996039391A1 (fr) * 1995-06-06 1996-12-12 American Home Products Corporation Derives de styryl benzimidazole inhibiteurs de la proliferation des cellules musculaires lisses
WO1996039387A1 (fr) * 1995-06-06 1996-12-12 American Home Products Corporation Acrylonitriles diheterocycliques inhibiteurs de la proliferation des cellules des muscles lisses
EP0833629A2 (fr) * 1995-06-19 1998-04-08 Ontogen Corporation Derives d'acide aryl-acrylique convenant comme inhibiteurs de proteine-tyrosine-phosphatase
EP0833629A4 (fr) * 1995-06-19 1998-09-16 Ontogen Corp Derives d'acide aryl-acrylique convenant comme inhibiteurs de proteine-tyrosine-phosphatase
US7745468B2 (en) 2003-12-11 2010-06-29 Board of Regents, University of Texas Systems The Compounds for treatment of cell proliferative diseases
US8119827B2 (en) 2003-12-11 2012-02-21 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
US8648102B2 (en) 2003-12-11 2014-02-11 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
US9096499B2 (en) 2003-12-11 2015-08-04 Board Of Regents, The University Of Texas System Compounds for treatment of cell proliferative diseases
US8779151B2 (en) 2006-03-31 2014-07-15 The Board Of Regents Of The University Of Texas System Orally bioavailable caffeic acid related anticancer drugs
US8637675B2 (en) 2008-07-08 2014-01-28 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activators of transcription (STATS)
US9000179B2 (en) 2008-07-08 2015-04-07 Board Of Regents, The University Of Texas System Inhibitors of proliferation and activation of signal transducer and activator of transcription (STATs)
EP3429569A4 (fr) * 2016-03-17 2020-02-26 The Johns Hopkins University Méthodes destinées à prévenir ou à traiter la maladie de parkinson par farnésylation de paris

Also Published As

Publication number Publication date
AU662480B2 (en) 1995-09-07
CA2080582A1 (fr) 1991-10-17
EP0527181A4 (en) 1993-04-07
JPH05507072A (ja) 1993-10-14
IL97873A0 (en) 1992-06-21
EP0527181A1 (fr) 1993-02-17
AU7756891A (en) 1991-11-11

Similar Documents

Publication Publication Date Title
US5196446A (en) Certain indole compounds which inhibit EGF receptor tyrosine kinase
AU658567B2 (en) Styryl-substituted indole and pyridyl compounds
EP0580598B1 (fr) Composes heteroaryles substitues par styryle et inhibant la tyrosine-kinase du recepteur d'egf
US5656655A (en) Styryl-substituted heteroaryl compounds which inhibit EGF receptor tyrosine kinase
US5217999A (en) Styryl compounds which inhibit EGF receptor protein tyrosine kinase
US5710158A (en) Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1991016892A1 (fr) Composes de styryle inhibant la proteine tyrosine kinase de recepteur de facteur de croissance epidermique
US5714493A (en) Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
EP0584222B1 (fr) Composes aryle et heteroaryle bis monocycliques et/ou bicycliques qui inhibent la tyrosine kinase d'un recepteur du egf et/ou du pdgf
USRE37650E1 (en) Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
Traxler et al. [(Alkylamino) methyl] acrylophenones: potent and selective inhibitors of the epidermal growth factor receptor protein tyrosine kinase
JPH11507355A (ja) タンパク質チロシンキナーゼｈｅｒ−２の自己リン酸化能を選択的に阻害するアリール及びヘテロアリールキナゾリン化合物
AU662480B2 (en) Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase
JP2002516851A (ja) サイクリン依存性キナーゼを阻害する医薬製造のためのインジゴイドビスインドール誘導体の使用
JPH10509708A (ja) プロテイン・キナーゼのインヒビターとして有用な医薬ピラゾール組成物
US5418245A (en) Styryl-substituted monocyclic and bicyclic heteroaryl compounds which inhibit EGF receptor tyrosine kinase
FI100530B (fi) Menetelmä substituoitujen diaminoftaali-imidien ja niiden analogien va lmistamiseksi
US5476851A (en) Pyrazolo[3,4-g]quinoxaline compounds which inhibit PDGF receptor protein tyrosine kinase
MXPA97001820A (en) Compounds of pirazolo [3,4-g] quinoxaline queinhiben protein tyrosine kinase receptor dep
NZ204369A (en) Piperazine derivatives,their production,and pharmaceutical compositions which contain them
US4447607A (en) Dibenzo diazacines
IL99762A (en) Alpha-cyano-styryl-substituted pyridyl compounds which inhibit egf receptor tyrosine kinase and pharmaceutical compositions containing them
WO2005113561A1 (fr) Cyclicsulfonate pyrrole indolinones en tant qu'inhibiteurs de kinase

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU CA JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 2080582

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1991908779

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1991908779

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1991908779

Country of ref document: EP